Trump's vaccine order faces backlash from pharma industry and experts
President Trump's directive for vaccine manufacturers to split production has drawn sharp criticism from health organizations and experts, with the pharmaceutical industry also voicing concerns.
President Donald Trump's Monday directive aimed at vaccine manufacturers, ordering them to split and multiply vaccine production, has encountered widespread opposition. Healthcare experts and medical organizations have strongly criticized the order, labeling it "dangerous" and "unscientific." Assessments suggest the directive could jeopardize children's health.
The medical community has consistently opposed anti-vaccine and anti-science agendas promoted by President Trump and his appointed Health Secretary Robert F. Kennedy Jr., who lacks a background in science, medicine, or public health. For instance, the American Academy of Pediatrics has previously sued the Trump administration over changes to childhood vaccine recommendations.
A notable aspect of the backlash is the pharmaceutical industry's swift and direct response. While negative reactions from health professionals were anticipated, the pharmaceutical companies' unfavorable stance on Trump's actions has drawn attention.
The specifics of the order and its potential impact on vaccine manufacturing and distribution remain unclear, but the internal industry criticism suggests potential challenges in its implementation.